GoodRx Holdings, Inc. (GDRX) Análisis de acciones

Descripción de la empresa

GoodRx Holdings, Inc. operates within the healthcare sector, specifically functioning in the health information services industry by providing tools that allow consumers to compare prescription drug prices and reduce costs in the United States. The company's business model relies on a price comparison platform that offers curated, geographically relevant information to facilitate savings on medication purchases. In terms of scale, GoodRx Holdings holds a market capitalization of $702.28M and generates annual revenue of $796.85M based on trailing twelve-month data. With a workforce of 697 employees, the company's current market cap suggests a mid-sized entity within the broader healthcare technology landscape, while its revenue figure indicates a significant operational footprint that supports its service delivery across the market.

Salud financiera

GoodRx Holdings reported a revenue of $796.85M for the trailing twelve months, with a net income of $30.44M and an EBITDA of $122.31M, revealing a substantial gap between operating earnings and net profit that highlights the impact of non-operating expenses or tax obligations on the bottom line. The company generated free cash flow of $81.94M, which provides a strong foundation for financial flexibility and the ability to fund operations or strategic initiatives without relying heavily on external financing. The company demonstrates high efficiency in production with a gross margin of 92.8%, while the operating margin sits at 19.0% and the profit margin is 3.8%, indicating that a significant portion of revenue is consumed by operating expenses and other costs before reaching the final net income. Regarding liquidity and leverage, GoodRx Holdings holds $261.82M in cash against $542.81M in total debt, resulting in a debt-to-equity ratio of 88.08, which characterizes a balance sheet with significant leverage relative to its equity base. The current ratio stands at 2.61, suggesting that the company possesses more than double the current assets necessary to cover its short-term liabilities, indicating robust short-term liquidity. Return on equity is recorded at 4.5% and return on assets at 4.8%, metrics that reveal the current effectiveness of management in generating profits from the shareholders' equity and the total asset base, respectively.

Evaluación de valoración

The trailing P/E ratio is 22.78, whereas the forward P/E is significantly lower at 5.58, implying that the market expects a substantial contraction in earnings or a re-rating of valuation multiples rather than an expansion in the near term. The price-to-book ratio is 1.13, indicating that the stock trades at a slight premium over its book value, suggesting that the market assigns some value to the company's intangible assets or future growth potential beyond its tangible net worth. Alternative valuation metrics further illustrate the market's perspective, with a price-to-sales ratio of 0.88 and an EV/EBITDA of 8.04, suggesting that the company is valued conservatively relative to its sales and earnings power when enterprise value is considered. The stock has exhibited significant volatility within the past year, trading between a 52-week high of $5.81 and a 52-week low of $1.77, placing the current valuation context within this wide historical range. The beta of 1.47 indicates that the stock price is more volatile than the broader market, moving with greater intensity than the S&P 500 index during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year is negative at -1.9%, while earnings growth year-over-year is even more negative at -9.7%, implying that profitability is declining at a faster rate than revenue, which could signal rising cost pressures or margin compression. As a non-dividend payer, GoodRx Holdings reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company currently retains all earnings rather than distributing them to shareholders. This retention strategy suggests the company is focusing on reinvesting its financial resources into business operations or balance sheet strengthening rather than providing income to investors. Overall, the company presents a growth and income profile characterized by negative growth rates and a complete absence of dividend distributions, focusing entirely on capital retention and operational execution.